|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TSHZ2 |
Gene summary for TSHZ2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TSHZ2 | Gene ID | 128553 |
| Gene name | teashirt zinc finger homeobox 2 | |
| Gene Alias | C20orf17 | |
| Cytomap | 20q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9NRE2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 128553 | TSHZ2 | GSM4909285 | Human | Breast | IDC | 8.25e-07 | -2.28e-01 | 0.21 |
| 128553 | TSHZ2 | GSM4909286 | Human | Breast | IDC | 3.78e-06 | -2.32e-01 | 0.1081 |
| 128553 | TSHZ2 | GSM4909287 | Human | Breast | IDC | 1.18e-03 | -2.12e-01 | 0.2057 |
| 128553 | TSHZ2 | GSM4909290 | Human | Breast | IDC | 3.79e-02 | -2.26e-01 | 0.2096 |
| 128553 | TSHZ2 | GSM4909294 | Human | Breast | IDC | 1.45e-03 | -2.00e-01 | 0.2022 |
| 128553 | TSHZ2 | GSM4909296 | Human | Breast | IDC | 4.04e-02 | -2.19e-01 | 0.1524 |
| 128553 | TSHZ2 | GSM4909297 | Human | Breast | IDC | 3.21e-03 | -2.24e-01 | 0.1517 |
| 128553 | TSHZ2 | GSM4909299 | Human | Breast | IDC | 2.04e-20 | 5.38e-01 | 0.035 |
| 128553 | TSHZ2 | GSM4909300 | Human | Breast | IDC | 4.79e-03 | 3.79e-01 | 0.0334 |
| 128553 | TSHZ2 | GSM4909301 | Human | Breast | IDC | 3.78e-06 | -2.32e-01 | 0.1577 |
| 128553 | TSHZ2 | GSM4909304 | Human | Breast | IDC | 1.38e-03 | -2.28e-01 | 0.1636 |
| 128553 | TSHZ2 | GSM4909308 | Human | Breast | IDC | 1.23e-02 | -2.22e-01 | 0.158 |
| 128553 | TSHZ2 | GSM4909309 | Human | Breast | IDC | 5.19e-11 | 5.40e-01 | 0.0483 |
| 128553 | TSHZ2 | GSM4909311 | Human | Breast | IDC | 2.13e-03 | -2.01e-01 | 0.1534 |
| 128553 | TSHZ2 | GSM4909312 | Human | Breast | IDC | 3.78e-06 | -2.32e-01 | 0.1552 |
| 128553 | TSHZ2 | GSM4909313 | Human | Breast | IDC | 3.22e-02 | 3.05e-01 | 0.0391 |
| 128553 | TSHZ2 | GSM4909315 | Human | Breast | IDC | 1.72e-05 | -2.32e-01 | 0.21 |
| 128553 | TSHZ2 | GSM4909319 | Human | Breast | IDC | 1.72e-05 | -2.25e-01 | 0.1563 |
| 128553 | TSHZ2 | GSM4909321 | Human | Breast | IDC | 8.07e-06 | -2.32e-01 | 0.1559 |
| 128553 | TSHZ2 | NCCBC14 | Human | Breast | DCIS | 2.79e-05 | -1.31e-01 | 0.2021 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Stomach | WIM |  |
| Stomach | SIM |  |
| Liver | NAFLD |  |
| Liver | Cirrhotic |  |
| Liver | HCC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TSHZ2 | SNV | Missense_Mutation | rs367984099 | c.2729N>T | p.Thr910Met | p.T910M | Q9NRE2 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
| TSHZ2 | SNV | Missense_Mutation | c.1894N>T | p.Asp632Tyr | p.D632Y | Q9NRE2 | protein_coding | deleterious(0.01) | benign(0.338) | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
| TSHZ2 | SNV | Missense_Mutation | novel | c.1367C>G | p.Ser456Cys | p.S456C | Q9NRE2 | protein_coding | tolerated(0.09) | possibly_damaging(0.533) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| TSHZ2 | SNV | Missense_Mutation | novel | c.2577G>T | p.Gln859His | p.Q859H | Q9NRE2 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TSHZ2 | SNV | Missense_Mutation | novel | c.2692C>T | p.His898Tyr | p.H898Y | Q9NRE2 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
| TSHZ2 | SNV | Missense_Mutation | novel | c.564A>C | p.Lys188Asn | p.K188N | Q9NRE2 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-BH-A0DI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| TSHZ2 | SNV | Missense_Mutation | c.2859N>A | p.Met953Ile | p.M953I | Q9NRE2 | protein_coding | tolerated(0.35) | benign(0.014) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| TSHZ2 | SNV | Missense_Mutation | novel | c.661N>G | p.Ser221Gly | p.S221G | Q9NRE2 | protein_coding | deleterious(0.05) | probably_damaging(0.982) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TSHZ2 | SNV | Missense_Mutation | c.529N>A | p.Leu177Met | p.L177M | Q9NRE2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A1F0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TSHZ2 | SNV | Missense_Mutation | c.356A>G | p.His119Arg | p.H119R | Q9NRE2 | protein_coding | tolerated(0.58) | benign(0.374) | TCGA-D8-A145-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 128553 | TSHZ2 | TRANSCRIPTION FACTOR | allopurinol | ALLOPURINOL | 29193002 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |